Medexus Pharmaceuticals Inc (MDP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 1,500 | 1,549 | 1,579 | 1,324 | 1,526 |
| Income taxes - deferred | -94 | -2,525 | N/A | -3,610 | 375 |
| Accounts receivable | -599 | 2,869 | 1,828 | 7,918 | -12,151 |
| Other Working Capital | -3,204 | 7,015 | -1,878 | 7,257 | -5,775 |
| Other Operating Activity | 679 | -5,337 | -8,344 | -8,726 | 13,704 |
| Operating Cash Flow | $-1,718 | $3,571 | $-6,815 | $4,163 | $-2,320 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -9 | -38 | -32 | -38 | -9 |
| Net Acquisitions | -91 | -81 | -132 | -313 | -112 |
| Purchase Sale Intangibles | -253 | N/A | -5,723 | -9,975 | -662 |
| Other Investing Activity | 0 | 0 | 0 | 1 | 0 |
| Investing Cash Flow | $-353 | $-119 | $-5,887 | $-10,325 | $-783 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 4,085 | N/A | N/A | -7,142 | 6,605 |
| Debt Repayment | -9 | -8 | -91 | -76 | -89 |
| Other Financing Activity | -599 | -5,355 | 4,180 | 21,307 | -462 |
| Financing Cash Flow | $3,477 | $-5,363 | $4,089 | $14,090 | $6,054 |
| Exchange Rate Effect | 28 | -151 | 108 | 2,015 | -322 |
| Beginning Cash Position | 8,137 | 10,199 | 18,704 | 9,351 | 6,722 |
| End Cash Position | 9,571 | 8,137 | 10,199 | 18,704 | 9,351 |
| Net Cash Flow | $1,406 | $-1,911 | $-8,613 | $7,927 | $2,951 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,718 | 3,571 | -6,815 | 4,163 | -2,320 |
| Capital Expenditure | -262 | -38 | -5,755 | -10,013 | -671 |
| Free Cash Flow | -1,980 | 3,533 | -12,570 | -5,850 | -2,991 |